Innate Pharma

Bristol-myers Squibb Compnay

Innate Pharma, S.a.

Cecile Bonnafous

Mathieu Blery

Hélène Sicard

Renaud Buffet

Laurent Gauthier

Carine Paturel

Ashok Kumar Gupta

Pascale Andre

Nadia Anceriz

Ivan Perrot

Michael Darron Robbins

Arnaud Dujardin

Luisa M Salter-Cid

Helene Sicard

The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma

The present invention relates to methods for detecting and monitoring NK cells in paraffin-embedded tissue samples. Also provided are antibodies, antibody fragments, and derivatives thereof that specifically bind to NKp46 present on the surface of NK cells in paraffin-embedded tissue samples.

Methods for detecting tissue infiltrating NK cells

The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.

Mica binding agents

Provided are methods for clinical treatment of multiple myeloma using an anti-KIR antibody in combination with an anti-CS 1 antibody.

Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma

Growing community of inventors

Marseilles, France

Cecile Bonnafous